Deferoxamine

Generic name
Deferoxamine
Brand name
ATC Code
V03AC01
Compare …

Deferoxamine

Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Pharmacokinetics in children

No studies have been carried out into the pharmacokinetic parameters of deferoxamine in children.

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

Available formulations

No information is present at this moment.

Dosages

Acute iron intoxication
  • Intravenous
    • 1 month up to 18 years
      [7]
      • Initial 10 - 15 mg/kg/hour, continuous infusion. Max: 80 mg/kg/day.
      • Duration of treatment:

        12 hours

      • Reduce the dose as soon as possible, usually after 4-6 hours. Dose depending on the ferritin concentration
Chelation therapy for beta-thalassaemia major
  • Subcutaneous
    • 1 month up to 18 years
      [1] [2] [4] [5] [6]
      • 25 - 50 mg/kg/dose, continuous infusion.

      • Allow the subcutaneous infusion to run in over 8-12 hours overnight. For 5-7 days per week. Dose depending on the ferritin concentration.
        There is no scientific evidence for applying deferoxamine in children younger than 2 years.

Renal impaiment in children > 3 months

GFR ≥10 ml/min/1.73m2: Dose adjustment not required.

GFR <10 ml/min/1.73m2: A general recommendation on dose adjustment cannot be provided.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects in children

Can colour the urine red. Disrupted sense of balance (dose-dependent). Growth retardation and bone conditions at higher doses and in young children.

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions in children

Check the bodyweight and the height gain of children every three months.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

ALL OTHER THERAPEUTIC PRODUCTS

This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.

Antidotes
V03AB15
V03AB14
Iron chelating agents
V03AC03
V03AC02
Detoxifying agents for antineoplastic treatment
V03AF03
V03AF01
V03AF07
Drugs for treatment of hypoglycemia
V03AH01
DETOXIFYING AGENTS FOR ANTINEOPLASTIC TREATMENT
V03AF03
V03AF01
V03AF07

References

  1. Aydinok Y, et al, A randomized controlled 1-year study of daily deferiprone plus twice weekly desferrioxamine compared with daily deferiprone monotherapy in patients with thalassemia major, Haematologica. , 2007 , Dec;92(12), 1599-606
  2. Cappellini MD, et al, Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia, Clin Ther, 2007 , May;29(5), 909-17
  3. Cario H, et al, Recent developments in iron chelation therapy, Klin Padiatr, 2007 , May-Jun;219(3), 158-65
  4. Graziano JH, et al, Chelation therapy in beta-thalassemia major. I. Intravenous and subcutaneous deferoxamine, J Pediatr, 1978, Apr;92(4), 648-52
  5. Walter PB, et al, Inflammation and oxidant-stress in beta-thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial, Haematologica, 2008, Jun;93(6), 817-25
  6. Yarali N, et al, Subcutaneous bolus injection of deferoxamine is an alternative method to subcutaneous continuous infusion, J Pediatr Hematol Oncol, 2006, Jan;28(1), 11-6
  7. Novartis Pharma B.V., SmPC Desferal (RVG 03984) 16-09-2019, www.geneesmiddeleninformatiebank.nl

Changes

Therapeutic Drug Monitoring


Overdose